Evotec Inkomsten in het verleden

Verleden criteriumcontroles 0/6

De winst van Evotec is gedaald met een gemiddeld jaarlijks percentage van -51.5%, terwijl de winst van de Life Sciences -industrie jaarlijks groeide met 13.9%. De inkomsten zijn groeide met een gemiddeld percentage van 13.8% per jaar.

Belangrijke informatie

-51.5%

Groei van de winst

-51.4%

Groei van de winst per aandeel

Life Sciences Groei van de industrie	26.8%
Inkomstengroei	13.8%
Rendement op eigen vermogen	-17.7%
Nettomarge	-22.1%
Laatste winstupdate	30 Sep 2024

Recente prestatie-updates uit het verleden

Recent updates

Evotec SE (ETR:EVT) Stock's 45% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Aug 08

We Think Evotec (ETR:EVT) Has A Fair Chunk Of Debt

Aug 03

Investors Aren't Entirely Convinced By Evotec SE's (ETR:EVT) Revenues

Apr 10

These 4 Measures Indicate That Evotec (ETR:EVT) Is Using Debt Reasonably Well

Mar 05

A Piece Of The Puzzle Missing From Evotec SE's (ETR:EVT) Share Price

Jan 09

We Think Evotec (ETR:EVT) Can Stay On Top Of Its Debt

Oct 05

Evotec (ETR:EVT) Has A Somewhat Strained Balance Sheet

Jun 28

Is There An Opportunity With Evotec SE's (ETR:EVT) 37% Undervaluation?

May 14

Does Evotec (ETR:EVT) Have A Healthy Balance Sheet?

Feb 25

Evotec (ETR:EVT) Seems To Use Debt Quite Sensibly

Jul 29

Is Now The Time To Look At Buying Evotec SE (ETR:EVT)?

May 16

Is Evotec (ETR:EVT) A Risky Investment?

Apr 28

Opbrengsten en kosten

Hoe Evotec geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

XTRA:EVT Opbrengsten, kosten en inkomsten (EUR Millions )
Datum	Inkomsten	Inkomsten	G+A Uitgaven	R&D-uitgaven
30 Sep 24	777	-171	180	61
30 Jun 24	788	-171	173	67
31 Mar 24	777	-91	173	66
31 Dec 23	781	-84	170	69
30 Sep 23	821	-95	174	70
30 Jun 23	798	-103	177	71
31 Mar 23	800	-116	167	77
31 Dec 22	751	-176	156	77
30 Sep 22	698	-180	144	74
30 Jun 22	684	2	126	74
31 Mar 22	650	90	116	72
31 Dec 21	618	216	105	72
30 Sep 21	571	247	90	71
30 Jun 21	541	112	87	70
31 Mar 21	515	42	81	67
31 Dec 20	501	6	77	64
30 Sep 20	485	14	78	63
30 Jun 20	470	35	72	59
31 Mar 20	462	42	68	59
31 Dec 19	446	38	66	58
30 Sep 19	419	61	62	56
30 Jun 19	404	77	60	55
31 Mar 19	398	94	58	45
31 Dec 18	375	84	57	36
30 Sep 18	370	63	54	26
30 Jun 18	338	31	54	19
31 Mar 18	294	20	48	18
31 Dec 17	264	23	42	18
30 Sep 17	215	28	39	18
30 Jun 17	193	35	31	18
31 Mar 17	178	36	29	18
31 Dec 16	165	28	27	18
30 Sep 16	160	18	24	18
30 Jun 16	148	6	25	19
31 Mar 16	144	17	25	19
31 Dec 15	128	17	25	18
30 Sep 15	119	12	24	17
30 Jun 15	104	11	21	15
31 Mar 15	93	-4	19	13
31 Dec 14	89	-7	18	12
30 Sep 14	85	-29	17	11
30 Jun 14	89	-25	17	11
31 Mar 14	86	-27	17	10
31 Dec 13	86	-25	17	10

Kwaliteitswinsten: EVT is momenteel verliesgevend.

Groeiende winstmarge: EVT is momenteel verliesgevend.

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: EVT is verliesgevend en de verliezen zijn de afgelopen 5 jaar toegenomen met een snelheid van 51.5% per jaar.

Versnelling van de groei: Het is niet mogelijk om de winstgroei van EVT over het afgelopen jaar te vergelijken met het gemiddelde over de afgelopen vijf jaar, omdat het bedrijf momenteel verliesgevend is.

Winst versus industrie: EVT is verlieslatend, waardoor het lastig is om de winstgroei van het afgelopen jaar te vergelijken met die van de Life Sciences industrie ( 5.4% ).

Rendement op eigen vermogen

Hoge ROE: EVT heeft een negatief Return on Equity ( -17.69% ), omdat het momenteel verliesgevend is.

Evotec Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Belangrijke informatie

Recente prestatie-updates uit het verleden

Second quarter 2024 earnings: EPS misses analyst expectations

Evotec SE to Report Nine Months, 2024 Results on Nov 08, 2024

Full year 2023 earnings: EPS misses analyst expectations

Evotec SE to Report Fiscal Year 2023 Results on Apr 24, 2024

Evotec SE to Report Q1, 2024 Results on May 22, 2024

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Recent updates

Consensus EPS estimates fall by 54%

Halozyme Therapeutics, Inc. (NasdaqGS:HALO) made a non-binding expression of interest to acquire Evotec SE (XTRA:EVT) for €2 billion.

Triton Reportedly Weighs Takeover Deal for Drug Developer Evotec

Evotec SE (ETR:EVT) Just Reported Earnings, And Analysts Cut Their Target Price

Monacum Partners GmbH acquired Evotec Drug Substance (Germany) GmbH from Evotec SE (XTRA:EVT).

A Piece Of The Puzzle Missing From Evotec SE's (ETR:EVT) 32% Share Price Climb

Price target decreased by 22% to €10.65

Consensus EPS estimates fall by 13%

Evotec SE Announces Change in Management Board, Effective 01 October 2024

Price target decreased by 11% to €13.64

Consensus EPS estimates fall by 69%

Evotec SE (ETR:EVT) Just Reported Earnings, And Analysts Cut Their Target Price

Second quarter 2024 earnings: EPS misses analyst expectations

Consensus EPS estimates fall by 77%

Evotec SE (ETR:EVT) Stock's 45% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Evotec SE Updates Earnings Guidance for the Fiscal Year 2024

We Think Evotec (ETR:EVT) Has A Fair Chunk Of Debt

Price target decreased by 7.0% to €19.26

Aurobac Therapeutics, founded by Boehringer Ingelheim, bioMerieux and Evotec, Names Scientific Advisory Board

Evotec SE to Report Nine Months, 2024 Results on Nov 08, 2024

Evotec SE, Annual General Meeting, Jun 10, 2024

Evotec SE announced delayed 20-F filing

Full year 2023 earnings: EPS misses analyst expectations

Evotec SE Provides Earnings Guidance for the Year 2024

Evotec SE Welcomes Aurélie Dalbiez as Chief People Officer, Effective 15 June 2024

Evotec SE to Report Fiscal Year 2023 Results on Apr 24, 2024

Investors Aren't Entirely Convinced By Evotec SE's (ETR:EVT) Revenues

Price target decreased by 7.5% to €23.00

These 4 Measures Indicate That Evotec (ETR:EVT) Is Using Debt Reasonably Well

Price target decreased by 7.6% to €23.67

Price target decreased by 8.3% to €24.88

Evotec SE to Report Q1, 2024 Results on May 22, 2024

Price target decreased by 9.1% to €27.14

A Piece Of The Puzzle Missing From Evotec SE's (ETR:EVT) Share Price

Evotec SE Announces Zhejiang Jingxin Pharmaceutical Co., Ltd Receives Approval for EVT201 in China

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New minor risk - Share price stability

Evotec SE to Report Nine Months, 2023 Results on Nov 08, 2023

We Think Evotec (ETR:EVT) Can Stay On Top Of Its Debt

Second quarter 2023 earnings released: €0.084 loss per share (vs €0.16 loss in 2Q 2022)

Evotec SE (XTRA:EVT) acquired remaining 50% stake in NephTera Gmbh from Vifor (International) AG for €1.65 million.

Evotec SE Provides Revenue Guidance for the Full Year 2023

Evotec SE Revises Earnings Guidance for the Fiscal Year 2023

Evotec (ETR:EVT) Has A Somewhat Strained Balance Sheet

Evotec SE, Annual General Meeting, Jun 20, 2023

Is There An Opportunity With Evotec SE's (ETR:EVT) 37% Undervaluation?

Price target decreased by 8.1% to €24.93

Price target decreased by 9.8% to €24.73

Does Evotec (ETR:EVT) Have A Healthy Balance Sheet?

Evotec SE Appoints Laetitia Rouxel as Member of the Management Board, Effective 01 April 2023

Price target decreased to €26.72

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Evotec SE Reaffirms Earnings Guidance for the Full Year 2022

Price target decreased to €30.94

Consensus forecasts updated

Evotec Launches PanOmics Data Analysis Platform PanHunter At Bio-IT World

Price target decreased to €32.50

Evotec SE (XTRA:EVT) agreed to acquire Central Glass Germany GmbH from Central Glass Co., Ltd. (TSE:4044) for €1.

Consensus forecasts updated

Consensus EPS estimates have been upgraded.

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Evotec SE Revises Revenue Guidance for the Full Year 2022

Consensus forecasts updated

Evotec (ETR:EVT) Seems To Use Debt Quite Sensibly

Now 20% undervalued

Evotec SE (XTRA:EVT) completed the acquisition of Rigenerand S.R.L. from Xyence Capital SGR and others.

Now 22% undervalued after recent price drop

Evotec Se Appoints Camilla Macapili Languille as New Member of Supervisory Board

Now 22% undervalued after recent price drop